{"doi":"10.1002/alz.12759","title":"Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease","abstract":"INTRODUCTION: This increasing body of literature indicates that menopause hormonal replacement therapy (MHT) may substantially mitigate the risk of developing late-life cognitive decline due to progressive Alzheimer's disease (AD) pathophysiology. For the first time, we investigated the question whether MHT impacts AD biomarker-informed pathophysiological dynamics in de-novo diagnosed menopausal women. METHODS: We analyzed baseline and longitudinal differences between MHT-taking and -not women in terms of concentrations of core pathophysiological AD plasma biomarkers, validated in symptomatic and cognitively healthy individuals, including biomarkers of (1) the amyloid-β (Aβ) pathway, (2) tau pathophysiology, (3) neuronal loss, and (4) axonal damage and neurodegeneration. RESULTS: We report a prominent and significant treatment response at the Aβ pathway biomarker level. Women at genetic risk for AD (APOE e4 allele carriers) have particularly shown favorable results from treatment. DISCUSSION: To our knowledge, we present first prospective clinical evidence on effects of MHT on AD pathophysiology during menopause.","journal":"Alzheimer s & Dementia","year":2022,"id":238383,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":55,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9422,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":282615,"name":"Andrea Vergallo","orcid":"0000-0002-0208-6384","position":1,"is_corresponding":false},{"id":693817,"name":"Pablo Lemercier","orcid":"0000-0003-1722-8303","position":2,"is_corresponding":false},{"id":282616,"name":"Simone Lista","orcid":"0000-0001-6804-7858","position":3,"is_corresponding":false},{"id":276903,"name":"Andréa Lessa Benedet","orcid":"0000-0001-8219-1741","position":4,"is_corresponding":false},{"id":241104,"name":"Nicholas J. Ashton","orcid":"0000-0002-3579-8804","position":5,"is_corresponding":false},{"id":505404,"name":"Enrica Cavedo","orcid":null,"position":6,"is_corresponding":false},{"id":27601,"name":"Henrik Zetterberg","orcid":"0000-0003-3930-4354","position":7,"is_corresponding":false},{"id":27600,"name":"Kaj Blennow","orcid":"0000-0002-1890-4193","position":8,"is_corresponding":false},{"id":839577,"name":"Eugeen Vanmechelen","orcid":"0000-0002-9466-5366","position":9,"is_corresponding":false},{"id":282617,"name":"Harald Hampel","orcid":"0000-0003-0894-8982","position":10,"is_corresponding":false},{"id":862651,"name":"the Neurodegeneration Precision Medicine Initiative (NPMI)","orcid":null,"position":11,"is_corresponding":false},{"id":645231,"name":"Herman Depypere","orcid":null,"position":0,"is_corresponding":true}],"reference_count":71,"raw_metadata":null,"created_at":"2026-07-19T00:22:26.932537Z","pmid":"36218064","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}